AI model aims to predict lung disease progression
NCT ID NCT07404423
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will collect data from 1000 people with idiopathic pulmonary fibrosis (IPF) across multiple Italian centers. Researchers will use machine learning to build a model that predicts disease progression, acute flare-ups, and response to treatment. The goal is to improve risk assessment for patients with this progressive lung disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a tool that helps doctors better predict how IPF will progress in individual patients, enabling more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. The machine-learning model may not be accurate enough for real-world use, and results may not apply outside the study population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care